Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 147

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 147
---
 condensed
consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

    For the Three Months Ended  
    Variance 

    September 30,  2025  
    September 30,  2024  
    September 30,  2025  
    September 30,  2024 
  
    Expenses: 

    Research and development 
    $816,697  
    $91,911  
    $724,786  
     789%
  
    General and administrative 
     1,480,356  
     401,636  
     1,078,720  
     269%
  
    Total operating expenses 
     2,297,053  
     493,547  
     1,803,506  
     365%

    Loss from operations 
     (2,297,053) 
     (493,547) 
     (1,803,506) 
     365%

    Other Income (Expenses): 

    Interest income 
     10,212  
     23  
     10,189  
     44300%
  
    Gain on change in fair value of derivative liability 
     -  
     9,885  
     (9,885) 
     -100%
  
    Interest expense 
     (1,193) 
     (107,382) 
     106,189  
     -99%
  
    Gain on extinguishment of debt 
     -  
     -  
     -  
     - 
  
    Other income 
     -  
     -  
     -  
     - 
  
    Total other income (expenses), net 
     9,019  
     (97,474) 
     106,493  
     -109%

    Net (loss) income 
    $(2,288,034) 
    $(591,021) 
    $(1,697,013) 
     287%

Research
and Development Expenses

Research
and development (“R&D”) expenses were $816,697 for three months ended September 30, 2025 compared to $91,911 for three
months ended September 30, 2024, representing an increase of $724,786, or 789